Vandetanib News and Research

RSS
Vandetanib is a substance being studied in the treatment of lung cancer and other types of cancer. It may block the growth and spread of tumor cells and prevent the growth of new blood vessels that tumors need to grow. Vandetanib is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Zactima.
Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

Study findings have potential to advance treatments for small cell lung cell cancer

Study findings have potential to advance treatments for small cell lung cell cancer

EGFR biomarkers predict NSCLC response to vandetanib

EGFR biomarkers predict NSCLC response to vandetanib

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib delays disease progression in elderly NSCLC patients

Added benefit of thyroid cancer drug vandetanib not proven

Added benefit of thyroid cancer drug vandetanib not proven

Study provides important details for recently identified target in lung adenocarcinoma

Study provides important details for recently identified target in lung adenocarcinoma

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

Vandetanib shows efficacy in thyroid cancer

Vandetanib shows efficacy in thyroid cancer

Hypoxic lung environment increases HIF-2a tumor growth signaling

Hypoxic lung environment increases HIF-2a tumor growth signaling

New approach to drug design may yield more effective and less toxic cancer medicines

New approach to drug design may yield more effective and less toxic cancer medicines

Scientists create cancer model built in the fruit fly Drosophila

Scientists create cancer model built in the fruit fly Drosophila

First trial to investigate new drug combination for NSCLC

First trial to investigate new drug combination for NSCLC

AstraZeneca selects Biologics as U.S. channel partner for vandetanib

AstraZeneca selects Biologics as U.S. channel partner for vandetanib

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

Research on rare cancers

Research on rare cancers

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA